LBL-051 / Oblenio Bio, Leads Biolabs - LARVOL DELTA

Oblenio Bio has dosed the first patients in a phase 1a first-in-human trial of LBL-051, a trispecific T-cell engager targeting B-cell maturation antigen (BCMA), CD19, and CD3 in patients with refractory autoimmune disease, the company announced. (BioPharm International)

Trial status • Immunology

Treatment with LBL-051-S3, a CD3/CD19/BCMA trispecific antibody, leads to a complete loss of plasma cells and B cells with minimal cytokine release in non-human primates (EULAR 2026) - "Conclusions The surrogate molecule LBL-051-S3 rapidly and completely depletes both peripheral and tissue CD19+ B cells and plasma cells in cynomolgus monkeys with minimal cytokine release. To our knowledge, this is the first NHP study showing complete tissue depletion of both cell types with a T cell engager molecule."

Trispecific • Immunology • Inflammation • SDC1